Workshop on evaluation of pediatric long-term neurocognitive development and medical products

Pharmacoepidemiol Drug Saf. 2017 Nov;26(11):1428-1430. doi: 10.1002/pds.4306. Epub 2017 Sep 19.

Authors

Ann W McMahon¹, Leonard P Kapcala², Philip H Sheridan²

Affiliations

¹ Office of Pediatric Therapeutics, Food and Drug Administration, Silver Spring, MD, USA.
² Division of Neurology Products, Food and Drug Administration, Silver Spring, MD, USA.

No abstract available

Publication types

Research Support, U.S. Gov't, P.H.S.

MeSH terms

Age Factors
Animals
Behavior, Animal / drug effects
Child
Child Behavior / drug effects
Child Development / drug effects*
Child Development / physiology
Clinical Trials as Topic
Cognition / drug effects
Cognition / physiology
Cognitive Dysfunction / chemically induced
Cognitive Dysfunction / diagnosis*
Cognitive Dysfunction / prevention & control
Cognitive Dysfunction / psychology
Congresses as Topic
Drug Evaluation, Preclinical / methods*
Drug-Related Side Effects and Adverse Reactions / diagnosis*
Drug-Related Side Effects and Adverse Reactions / prevention & control
Drug-Related Side Effects and Adverse Reactions / psychology
Humans
Models, Animal
Neuropsychological Tests*
Time Factors

Grants and funding

FD999999/Intramural FDA HHS/United States